Background/Objectives: Driving performance and competence represent a complex functional domain that may be affected in some individuals with schizophrenia. This scoping review aimed to map existing evidence characterizing driving-related functioning by identifying the cognitive, pharmacological and functional factors that influence driving ability and by synthesizing findings from experimental, neurocognitive and population-based studies. Methods: A structured search of the PubMed, Scopus and ScienceDirect databases was performed in accordance with PRISMA-ScR guidelines to identify studies published between 2015 and 2025 that examined cognitive, pharmacological and functional dimensions of driving in individuals with schizophrenia. Extracted data were narratively and thematically synthesized. Eleven studies met the inclusion criteria. Results: Findings clustered into three domains: cognitive, including attention, executive function, reaction time and visuospatial processing; pharmacological, encompassing drug comparisons, dosage, side effects and treatment stability; and functional, covering license status, driving participation, driving cessation, avoidance behaviors and self-regulation. Conclusions: This review integrates current evidence within a multidimensional and conditional framework, highlighting interactions between cognitive functioning, pharmacological factors, and compensatory self-regulation in individuals with schizophrenia. Understanding these interrelations may inform individualized fitness-to-drive evaluations and contribute to structured, context-sensitive interpretation of driving-related evidence in clinical and regulatory settings.

Background/Objectives: Cognitive impairment is a core feature of schizophrenia and is closely associated with everyday functioning and participation. This study examined the effects of a 12-week occupation-based group occupational therapy intervention on cognitive functioning in adults with schizophrenia. Methods: In this two-arm randomized controlled trial, 86 adults with schizophrenia were randomly allocated to an intervention group (n = 44) or a treatment-as-usual control group (n = 42). The intervention combined cognitive activation with everyday tasks, problem-solving, and social and creative activities. Co-primary outcomes were the Mini-Mental State Examination (MMSE), Addenbrooke’s Cognitive Examination III (ACE-III) total score, and Clock Drawing Test (CDT). Secondary outcomes included the Mini-Addenbrooke’s Cognitive Examination (M-ACE), ACE-III domains, and Trail Making Test (TMT) Parts A and B completion times and error counts, assessed at baseline and post-intervention. Group × time effects were examined using repeated-measures analysis of variance. Results: All 86 participants completed the post-intervention assessment and were included in the analysis. Compared with treatment as usual alone, the intervention was associated with significantly greater improvements in MMSE, ACE-III total, M-ACE, TMT Part A completion time, and the ACE-III language and visuospatial domains. Partial η² values ranged from 0.17 to 0.43, with the largest effect observed for the ACE-III total score. Conclusions: Adding occupation-based group occupational therapy to usual care may improve global and domain-specific cognitive test performance in adults with schizophrenia. Further research should determine whether these changes are maintained and translate into everyday occupational performance and participation. This trial was retrospectively registered with ISRCTN (ISRCTN43725423).

Background/Objectives: The COVID-19 pandemic posed significant challenges to quality of life, particularly for individuals living with chronic physical and/or mental conditions. Psychological factors such as fear of COVID-19, psychological distress, and resilience may be associated with quality-of-life outcomes during prolonged public health crises. This study aimed to examine quality of life and its psychological correlates among individuals with chronic conditions during the later phases and aftermath of the COVID-19 pandemic crisis. Methods: A cross-sectional study was conducted among 293 adults with chronic physical and/or mental conditions attending the General Hospital of Argolida, Greece. Participants completed validated self-report measures assessing quality of life (MVQOLI), fear of COVID-19 (FCV-19S), depression, anxiety, and stress (DASS-21), and psychological resilience (CD-RISC-25). Descriptive statistics, Spearman correlation analyses, and multivariable regression models were used to examine associations and identify factors associated with quality-of-life domains. Results: Higher levels of fear of COVID-19 and depressive symptoms were significantly associated with poorer quality of life across multiple domains. Depressive symptoms showed consistent negative associations with functional, interpersonal, transcendent, and overall quality-of-life scores. In contrast, psychological resilience was positively associated with interpersonal, transcendent, and overall quality of life. Regression analyses showed that depressive symptoms were negatively associated with overall quality of life, while resilience was independently associated with better quality-of-life outcomes. Conclusions: Psychological distress, particularly depressive symptoms and fear related to COVID-19, was associated with lower quality of life among individuals with chronic conditions during the later phases and aftermath of the COVID-19 crisis. Psychological resilience was positively associated with better quality-of-life outcomes, underscoring its relevance for supporting well-being during and after public health crises.